<DOC>
	<DOCNO>NCT02862548</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , efficacy tenofovir alafenamide ( TAF ) versus tenofovir disoproxil fumarate ( TDF ) -containing regimens participant chronic hepatitis B virus ( HBV ) infection Stage 2 great chronic kidney disease receive liver transplant .</brief_summary>
	<brief_title>Efficacy Safety Tenofovir Alafenamide ( TAF ) Versus Tenofovir Disoproxil Fumarate ( TDF ) -Containing Regimens Participants With Chronic Hepatitis B Virus ( HBV ) Infection Stage 2 Greater Chronic Kidney Disease Who Have Received Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Must ability understand sign write informed consent form ; consent must obtain prior initiation study procedure Documented evidence chronic HBV infection prior transplantation Primary secondary ( retransplant ) , liver alone liver kidney transplant recipient decease live donor Liver Transplant ≥ 12 week prior screen Maintained TDF alone combination approve antiviral HBV prophylaxis treatment Have approve HBV oral antiviral ( OAV ) treatment least 12 week posttransplant prior screening , HBV DNA &lt; low limit quantification ( LLOQ ) screen Screening eGFR_CKDEPI &lt; 90 ml/min/1.73m2 Male participant female participant childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Women consider child bear potential must negative serum pregnancy test Screening negative urine test Baseline dosing Must willing able comply study requirement Key Multiorgan transplant include heart lung recipient ( participant liver transplant part liverkidney dual transplant eligible enroll ) Participants history de novo recurrent hepatocellular carcinoma ( HCC ) posttransplant screen Histological evidence unresolved transplant rejection Current , uncontrolled ascites , variceal hemorrhage , hepatic encephalopathy , hepatorenal syndrome , hepatopulmonary syndrome , sign decompensated cirrhosis Participants meet follow laboratory parameter screen : Alanine aminotransferase ( ALT ) &gt; 10× upper limit normal ( ULN ) International normalize ratio ( INR ) &gt; 1.5 × ULN unless participant stable anticoagulant regimen affect INR Albumin &lt; 3.0 g/dL Direct bilirubin ≥ 4 × ULN Platelet count &lt; 50,000/mL Coinfection HIV hepatitis C virus ( HCV ) Recent ( within 4 week Screening ) episode infection require systemic antibiotic Use plan use Tcell depleting/masking antibody , systemic antineoplastic agent , cyclosporine &gt; 300 mg/day , use prohibit medication list within 28 day Baseline/Day 1 visit Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( e.g. , basal cell skin cancer , etc . ) hepatocellular carcinoma . Participants evaluation possible malignancy eligible Significant cardiovascular , pulmonary , neurological disease Use investigational agent within 3 month screen , unless allow Sponsor Use prohibit medication Current alcohol substance abuse judge investigator potentially interfere participant compliance Known hypersensitivity study drug , metabolite formulation excipients Lactating female may wish become pregnant course study NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>